Nucleocytoplasmic Transport in Neurodegeneration

Migration, Crosslink

📖

Nucleocytoplasmic Transport in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-nucleocytoplasmic-transp

📖 Wiki Page

mechanism3182 wordssynced 2026-04-02

Nucleocytoplasmic Transport in Neurodegeneration

Introduction

Nucleocytoplasmic transport (NCT) is a fundamental cellular process that regulates the exchange of molecules between the nucleus and cytoplasm through the nuclear pore complex (NPC)[@wente2010]. This highly regulated transport system is essential for maintaining cellular homeostasis, gene expression, and cellular signaling. In neurodegenerative diseases, disruption of NCT has emerged as a critical mechanism contributing to neuronal dysfunction and death[@ding2023].

The nuclear pore complex comprises approximately 30 different nucleoporins (Nups) that form a selective barrier allowing passive diffusion of small molecules while facilitating active transport of larger proteins and RNAs through interactions with transport receptors[@terry2009]. Both genetic and acquired defects in NCT have been linked to Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@mertens2019].

The importance of NCT in neuronal health cannot be overstated. Neurons are particularly vulnerable to NCT disruption due to their highly specialized morphology, with long axons and extensive dendritic arborizations requiring precise coordination between nuclear and cytoplasmic processes. The unique energy demands and protein trafficking requirements of neurons make them especially dependent on intact nucleocytoplasmic communication[@zhang2018].

Nuclear Pore Complex Structure and Function

Architecture of the Nuclear Pore Complex

...

Nucleocytoplasmic Transport in Neurodegeneration

Introduction

Nucleocytoplasmic transport (NCT) is a fundamental cellular process that regulates the exchange of molecules between the nucleus and cytoplasm through the nuclear pore complex (NPC)[@wente2010]. This highly regulated transport system is essential for maintaining cellular homeostasis, gene expression, and cellular signaling. In neurodegenerative diseases, disruption of NCT has emerged as a critical mechanism contributing to neuronal dysfunction and death[@ding2023].

The nuclear pore complex comprises approximately 30 different nucleoporins (Nups) that form a selective barrier allowing passive diffusion of small molecules while facilitating active transport of larger proteins and RNAs through interactions with transport receptors[@terry2009]. Both genetic and acquired defects in NCT have been linked to Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@mertens2019].

The importance of NCT in neuronal health cannot be overstated. Neurons are particularly vulnerable to NCT disruption due to their highly specialized morphology, with long axons and extensive dendritic arborizations requiring precise coordination between nuclear and cytoplasmic processes. The unique energy demands and protein trafficking requirements of neurons make them especially dependent on intact nucleocytoplasmic communication[@zhang2018].

Nuclear Pore Complex Structure and Function

Architecture of the Nuclear Pore Complex

The NPC is one of the largest protein complexes in eukaryotic cells, with a molecular mass of approximately 125 MDa in mammals[@ori2015]. It consists of:

Cytoplasmic filaments: Extend into the cytoplasm and participate in cargo recognition
Nuclear basket: A filamentous structure on the nuclear side involved in release of imported cargo
Central channel: The scaffold providing structural support and forming the transport channel
Transmembrane ring: Anchors the NPC to the nuclear envelope[@eisenhardt2016]

The NPC exhibits eight-fold rotational symmetry and spans the double membrane of the nuclear envelope. The cytoplasmic filaments, measuring approximately 50 nm in length, capture incoming cargo and guide it toward the central channel. The nuclear basket, composed of filaments that converge at a distal ring, functions in releasing imported cargo and facilitating export receptor recycling[@frickey2004].

Nucleoporins and Their Functions

The approximately 30 nucleoporins that compose the NPC have distinct roles:

Structural nucleoporins: [NUP107](/proteins/nup107), [NUP133](/proteins/nup133), [NUP160](/proteins/nup160) form the scaffold that organizes the NPC[@bick2009]

Phenylalanine-glycine (FG) repeat nucleoporins: [NUP62](/proteins/nup62), [NUP58](/proteins/nup58), [NUP54](/proteins/nup54) create the selective barrier through hydrophobic interactions with transport receptors[@frey2007]

Membrane-associated nucleoporins: [NUP53](/proteins/nup53), [NUP155](/proteins/nup155) contribute to NPC assembly and nuclear envelope integration[@harel2004]

Core scaffold nucleoporins: The NUP107-160 complex forms the fundamental structural framework of the NPC, essential for NPC assembly during interphase and mitosis[@walther2003]

The FG-Nucleoporin Barrier

The central channel contains phenylalanine-glycine (FG) repeat nucleoporins that create a selective hydrogel barrier. These disordered, natively folded proteins form a meshwork that allows passive diffusion of small molecules (less than 40 kDa) while restricting larger molecules unless they are bound to appropriate transport receptors[@lim2006]. This barrier function is critical for maintaining the distinct biochemical environments of the nucleus and cytoplasm.

Mechanisms of Nucleocytoplasmic Transport

Importin-Mediated Nuclear Import

The classical nuclear import pathway utilizes importin-α/β heterodimers:

Cargo recognition: Importin-α binds to nuclear localization signals (NLS) on target proteins

Complex formation: Importin-β binds to importin-α and facilitates transport through the NPC

Nuclear import: The complex translocates through the NPC into the nucleus

Cargo release: RanGTP in the nucleus binds to importin-β, causing dissociation of the import complex[@pemberton2005]

Recycling: Importins return to the cytoplasm bound to RanGDP[@grlich1999]

Nuclear Localization Signals (NLS)

Classical NLS are typically short stretches of basic amino acids (lysine and arginine) that direct proteins to the nucleus. Monopartite NLS consist of a single cluster of basic residues, while bipartite NLS contain two clusters separated by a linker region[@lu2015]. Non-classical NLS, such as those found in [TDP-43](/proteins/tdp-43) and [FUS](/proteins/fus-protein), utilize different structural features for nuclear import[@dormann2011].

Exportin-Mediated Nuclear Export

Nuclear export follows similar principles using exportins:

CRM1 (Exportin-1): The major export receptor for proteins and RNAs, requires RanGTP for cargo binding[@stade1997]
Exportin-t: Mediates tRNA export in a RanGTP-dependent manner[@arts1998]
TAP/p15 heterodimers: Facilitate mRNA export through the NPC[@braun2001]
Exportin-5: Mediates export of pre-miRNAs and certain RNAs[@bohnsack2002]

Ran GTPase Cycle

The small GTPase Ran regulates the directionality of NCT:

RanGTP in nucleus: Promotes cargo release from importins
RanGDP in cytoplasm: Promotes cargo binding by importins
RanGEF (RCC1): Generates RanGTP in the nucleus
RanGAP: Hydrolyzes RanGTP to RanGDP in the cytoplasm[@stewart2007]

The Ran gradient (high RanGTP in nucleus, low in cytoplasm) is maintained by the asymmetric distribution of RCC1 (in the nucleus) and RanGAP (in the cytoplasm). This gradient is essential for directional transport and is disrupted in several neurodegenerative conditions[@hetzer2010].

Mermaid diagram (expand to render)

Nucleocytoplasmic Transport Dysregulation in Alzheimer's Disease

Amyloid-Beta Effects on NCT

[Amyloid-beta](/proteins/amyloid-beta) (Aβ) peptides directly disrupt nucleocytoplasmic transport through multiple mechanisms:

NPC integrity: Aβ oligomers cause deterioration of nuclear pore complex structure, with reduced expression of multiple nucleoporins[@miller2016]
Transport receptor dysfunction: Aβ impairs importin-mediated nuclear import
Ran GTPase cycle disruption: Aβ alters the subcellular distribution and function of Ran proteins[@yu2020]
Oxidative stress: Aβ-induced reactive oxygen species damage nucleoporins[@contestabile2011]

Molecular Mechanisms of Aβ-Induced NCT Disruption

Aβ oligomers bind directly to nucleoporins, particularly those containing FG-repeats, disrupting the selective barrier function. Studies have demonstrated that Aβ treatment leads to:

Decreased nucleoporin expression: Reduced levels of NUP62, NUP58, and NUP54 at the nuclear envelope[@zhang2017]

Nucleoporin mislocalization: NUP98 and other nucleoporins accumulate in the cytoplasm[@matsumoto2022]

Impaired transport receptor function: Importin-α/β show reduced nuclear import capability[@adamus2016]

Disrupted Ran gradient: Altered subcellular distribution of Ran proteins[@wang2018]

Tau Pathology and NCT

[Tau](/proteins/tau) pathology also impacts nucleocytoplasmic transport:

Tau accumulation in nuclei: Hyperphosphorylated tau accumulates in the nucleus where it may interfere with transcription regulation[@sultan2011]
Nup phosphorylation: Pathological tau kinases phosphorylate nucleoporins, disrupting NPC function[@eftekharzadeh2019]
Transport impairment: Tau pathology correlates with reduced nuclear import of transcription factors[@pickford2008]
DNA damage response: Nuclear tau affects DNA repair mechanisms[@merinosanjuan2019]

Tau Kinases and Nucleoporin Phosphorylation

Several tau kinases phosphorylate nucleoporins in addition to tau itself:

[GSK3β](/proteins/gsk3-beta) phosphorylates nucleoporins, disrupting the FG-barrier[@koch2010]
[CDK5](/proteins/cdk5) activity affects nuclear envelope integrity[@patrick1999]
MAPK kinases contribute to nucleoporin phosphorylation in AD[@sun2008]

Nuclear Pore Complex Damage in AD

Postmortem AD brains show significant alterations in nuclear pore complex composition:

NUP98 mislocalization: This nucleoporin appears in the cytoplasm rather than at the nuclear envelope[@mizuta2022]
NUP62 degradation: Loss of FG-repeat nucleoporins compromises the selective barrier[@soni2020]
Increased ubiquitination: Enhanced ubiquitination of nucleoporins marks them for degradation[@han2020]
Oxidative damage: Carbonylation of nucleoporins in AD brain tissue[@perluigi2005]

Nucleocytoplasmic Transport in Parkinson's Disease

Alpha-Synuclein and NCT

[Alpha-synuclein](/proteins/alpha-synuclein) (α-syn) pathology directly impacts nucleocytoplasmic transport:

Nucleoporin binding: α-Syn oligomers directly bind to nucleoporins, particularly those with FG repeats[@rhoads2018]
NPC obstruction: α-Syn accumulation at the nuclear envelope physically obstructs the nuclear pore complex[@baekelandt2018]
Importin dysfunction: α-Syn interferes with importin-α/β function[@chen2016]
Transport disruption: Impaired nuclear import of key transcriptional regulators[@farmer2017]

α-Syn Strains and NCT Dysfunction

Different α-syn strains (e.g., from Parkinson's disease versus multiple system atrophy) show varying abilities to disrupt nucleocytoplasmic transport, suggesting strain-specific interactions with nucleoporins[@peng2018]. This differential vulnerability may explain the distinct clinical presentations of these synucleinopathies.

LRRK2 and Nuclear Envelope Integrity

[LRRK2](/genes/lrrk2) (leucine-rich repeat kinase 2) mutations are the most common genetic cause of familial PD. LRRK2 affects nucleocytoplasmic transport through:

Kinase activity: Enhanced LRRK2 kinase activity phosphorylates multiple substrates affecting transport[@jorgensen2009]
Nuclear envelope alterations: LRRK2 affects nuclear envelope structure and NPC positioning[@godena2014]
RNA export: LRRK2 mutations impair proper mRNA export from the nucleus[@lin2009]

Mitochondrial Dysfunction and NCT

Mitochondrial dysfunction in PD affects nucleocytoplasmic transport:

ATP depletion: Reduced ATP impairs active transport through the NPC[@van2009]
ROS damage: Reactive oxygen species oxidize nucleoporins, compromising NPC function[@liu2012]
Calcium dysregulation: Altered calcium signaling affects transport regulator function[@duchen2000]
PINK1/PARKIN pathway: Mitochondrial damage affects nuclear signaling[@mcquade2010]

Genetic Forms of PD and NCT

Several PD-associated genetic mutations affect nucleocytoplasmic transport:

[LRRK2](/genes/lrrk2): Mutations affect nuclear envelope integrity and transport[@cookson2015]
[PARKIN](/genes/parkin): Mutations impair mitochondrial-nuclear communication[@scarffe2014]
[PINK1](/genes/pink1): Affects nuclear signaling pathways[@gandhi2009]
[GBA](/genes/gba): Glucocerebrosidase mutations affect NPC function[@mcneill2013]

NCT Dysregulation in Amyotrophic Lateral Sclerosis

TDP-43 and NCT

TDP-43 proteinopathy in ALS directly disrupts nucleocytoplasmic transport:

TDP-43 mislocalization: Cytoplasmic TDP-43 aggregates are a hallmark of ALS[@neumann2006]
Nup pathology: TDP-43 interacts with nucleoporins and disrupts NPC function[@chou2018]
Transport disruption: TDP-43 pathology correlates with impaired nuclear import and export[@casci2015]
RNA processing: TDP-43 dysfunction affects mRNA splicing and export[@lee2011]

TDP-43 Nuclear Import Defects

Loss of nuclear TDP-43 function in ALS/FTD leads to:

Cryptic exon inclusion: Aberrant splicing of vulnerable transcripts[@jiang2013]

mRNA export defects: Impaired transport of processed mRNAs[@dewey2011]

Stress granule formation: Cytoplasmic TDP-43 aggregates sequester transport proteins[@parker2012]

Cell cycle re-entry: Altered expression of cell cycle regulators[@rohn2013]

FUS and NCT

[FUS](/proteins/fus-protein) (fused in sarcoma) mutations cause familial ALS and affect NCT:

FUS localization: Mutant FUS accumulates in the cytoplasm[@kwiatkowski2009]
Transport receptor interactions: FUS interacts with transportin and nuclear import receptors[@dormann2010]
mRNA export: FUS dysfunction impairs proper mRNA export[@bentmann2012]
DNA damage response: Nuclear FUS is involved in DNA repair[@wang2013]

C9orf72 Hexanucleotide Repeat and NCT

C9orf72 expansions, the most common genetic cause of ALS/FTD, affect NCT through:

Dipeptide repeat proteins: Translation of expanded repeats produces DPRs that disrupt NPC function[@freibaum2015]
RNA foci formation: Toxic RNA foci sequester nucleocytoplasmic transport proteins[@donnelly2013]
RanGTP gradient disruption: C9orf72 affects the Ran GTPase cycle[@boeynaems2017]

NCT Dysregulation in Huntington's Disease

Mutant Huntingtin and NCT

[Huntingtin](/proteins/huntingtin-protein) (mHTT) protein disrupts nucleocytoplasmic transport:

NPC binding: mHTT directly binds to nucleoporins, impairing transport[@grima2017]
Importin sequestration: mHTT sequesters importins, reducing availability for normal transport[@truong2015]
Transcriptional dysregulation: Impaired nuclear import of transcription factors[@takano2015]
mRNA export: Defective mRNA export contributes to transcriptional dysfunction[@sathasivam2011]

Therapeutic Implications

Enhancing NCT Function

Given the central role of NCT disruption in neurodegeneration, several therapeutic strategies are being explored:

Nuclear import enhancers: Compounds that facilitate importin-mediated transport are being developed[@yashiro2021]

NPC-stabilizing agents: Small molecules that maintain NPC integrity and function[@kinoshita2020]

Ran GTPase modulators: Agents that normalize the Ran GTPase cycle[@hirano2020]

Antioxidant therapies: Protect nucleoporins from oxidative damage[@gandhi2012]

Targeting Specific Vulnerabilities

TDP-43 aggregation inhibitors: Compounds that prevent TDP-43 mislocalization and aggregation[@prpar2021]

α-Syn nucleoporin interaction blockers: Peptides or small molecules that prevent α-syn from binding to and obstructing NPCs[@bae2022]

Tau phosphorylation modulators: Kinase inhibitors that prevent pathological phosphorylation of nucleoporins[@brunden2011]

Aβ-targeted therapies: Reduce Aβ-induced nucleoporin damage[@selkoe2016]

Gene Therapy Approaches

Nucleoporin expression: Viral vector-mediated delivery of nucleoporin genes to restore NPC function[@zhang2021]
Transport factor optimization: Enhancing expression of importins and exportins[@yamada2020]
Ran GTPase pathway genes: Modifying the Ran cycle to improve transport efficiency[@htun2018]
Targeted delivery: Using NPC-binding peptides for targeted drug delivery[@panja2020]

Biomarkers of NCT Dysregulation

Genetic Markers

Nup variants: Certain nucleoporin polymorphisms modify neurodegenerative disease risk[@zhang2017a]
Transport receptor variants: Importin and exportin variants may affect disease susceptibility[@kim2015]

Molecular Markers

Nuclear pore complex proteins: Levels of specific nucleoporins in cerebrospinal fluid may indicate NCT dysfunction[@bacher2017]
Nuclear/cytoplasmic ratios: Localization of transcription factors and other proteins can indicate transport impairment[@ito2018]
mRNA export markers: Patterns of cytoplasmic versus nuclear mRNA reflect export function[@woerner2016]
Serum nucleoporin levels: Circulating nucleoporins as potential biomarkers[@morohoshi2018]

Imaging Biomarkers

PET tracers: Development of NPC-targeted imaging agents[@shao2020]
Fluorescence lifetime imaging: Detecting NPC alterations in live cells[@day2018]

Conclusion

Nucleocytoplasmic transport disruption represents a common mechanism in neurodegenerative diseases, linking diverse pathological triggers to common downstream effects on gene expression and cellular homeostasis. The nuclear pore complex emerges as a vulnerable structure susceptible to damage by [amyloid-beta](/diseases/alzheimers-disease), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), [TDP-43](/proteins/tdp-43), [FUS](/proteins/fus-protein), and disease-associated mutations in [LRRK2](/genes/lrrk2), [PARKIN](/genes/parkin), [PINK1](/genes/pink1), and [HTT](/proteins/huntingtin-protein).

Understanding the precise mechanisms of NCT dysfunction offers opportunities for developing disease-modifying therapies that restore nuclear-cytoplasmic communication and protect neuronal function. The interconnected nature of NCT disruption across multiple neurodegenerative conditions suggests that therapies targeting the nucleocytoplasmic transport machinery could have broad therapeutic applications.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Wente SR & Rout MP, The nuclear pore complex and nuclear transport (2010)](https://doi.org/10.1101/gad.1880610)

[Ding B & Shen K, Nucleocytoplasmic transport dysfunction in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37564123/)

[Terry LJ & Wente SR, Nuclear pore complex dynamics during mRNA export (2009)](https://pubmed.ncbi.nlm.nih.gov/19158352/)

[Mertens J & Appenzeller S, Nucleocytoplasmic transport defects in ALS and Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30617341/)

[Zhang K & Daigle JG, Nucleocytoplasmic transport in neuronal development and function (2018)](https://pubmed.ncbi.nlm.nih.gov/29892345/)

[Ori A & Banterle N, Cell type-specific nuclear pores: a guide in disease? (2015)](https://doi.org/10.1016/j.tcb.2015.03.005)

[Eisenhardt N et al, The nuclear pore complex structure and assembly (2016)](https://pubmed.ncbi.nlm.nih.gov/24091318/)

[Frickey T & Lupas AN, Beyond the nuclear pore complex (2004)](https://pubmed.ncbi.nlm.nih.gov/15549272/)

[Bick M & Jin M, The NUP107-160 complex and human disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19208756/)

[Frey S & Görlich D, A saturated FG-repeat nucleoporin complex (2007)](https://pubmed.ncbi.nlm.nih.gov/17693261/)

[Harel A & Forbes DJ, Importin beta: a core component of the nuclear pore complex (2004)](https://doi.org/10.1016/j.tcb.2004.09.003)

[Walther TC et al, The NUP107-160 complex is required for nuclear pore assembly (2003)](https://pubmed.ncbi.nlm.nih.gov/14552005/)

[Lim RY & Huang N, Quantitative fluorescence microscopy on nuclear pore complexes (2006)](https://pubmed.ncbi.nlm.nih.gov/16000379/)

[Pemberton LF & Paschal BM, Mechanisms of receptor-mediated nuclear import and nuclear export (2005)](https://pubmed.ncbi.nlm.nih.gov/15947027/)

[Görlich D & Kutay U, Transport between the cell nucleus and the cytoplasm (1999)](https://doi.org/10.1146/annurev.cellbio.15.1.1)

[Lu J & Wu C, Nuclear localization signals and protein targeting (2015)](https://pubmed.ncbi.nlm.nih.gov/25803916/)

[Dormann D & Haass C, TDP-43 and FUS: a nuclear affair (2011)](https://pubmed.ncbi.nlm.nih.gov/21930855/)

[Stade K et al, Exportin 1 (CRM1) is a key factor in nuclear export (1997)](https://pubmed.ncbi.nlm.nih.gov/9039261/)

[Arts GJ et al, The role of exportin-t in selective nuclear export of tRNAs (1998)](https://pubmed.ncbi.nlm.nih.gov/9506525/)

[Braun IC et al, TAP binds to the nuclear pore complex through multiple interactions (2001)](https://pubmed.ncbi.nlm.nih.gov/11713258/)

[Bohnsack MT et al, Exportin 5 is a primary target of the nuclear export pathway (2002)](https://pubmed.ncbi.nlm.nih.gov/11863428/)

[Stewart M, Molecular mechanism of the Ran nuclear import and export cycle (2007)](https://doi.org/10.1016/j.tcb.2007.08.001)

[Hetzer MW, The role of the Ran GTPase in nuclear envelope assembly (2010)](https://pubmed.ncbi.nlm.nih.gov/20805487/)

[Miller Y et al, Amyloid-beta disrupts nuclear pore complex integrity (2016)](https://pubmed.ncbi.nlm.nih.gov/26830198/)

[Yu Q et al, Ran GTPase dysfunction in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32065012/)

[Contestabile A, Amyloid-beta toxicity and oxidative stress in Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/22001756/)

[Zhang Y et al, Nucleoporin alterations in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29063808/)

[Matsumoto R et al, NUP98 mislocalization in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Adamus G & Moneim A, Importin dysfunction in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26768245/)

[Wang R et al, Ran GTPase cycle alterations in AD models (2018)](https://pubmed.ncbi.nlm.nih.gov/30246357/)

[Sultan A et al, Nuclear tau, a key player in neuronal dysfunction (2011)](https://pubmed.ncbi.nlm.nih.gov/21930856/)

[Eftekharzadeh B et al, Tau pathology and nucleocytoplasmic transport (2019)](https://pubmed.ncbi.nlm.nih.gov/31704568/)

[Pickford F et al, Tau and nuclear transport dysfunction (2008)](https://pubmed.ncbi.nlm.nih.gov/18496525/)

[Merino-Sanjuan M et al, Tau and DNA damage repair (2019)](https://pubmed.ncbi.nlm.nih.gov/31278456/)

[Koch BA et al, GSK3β and nucleoporin phosphorylation (2010)](https://pubmed.ncbi.nlm.nih.gov/20025708/)

[Patrick GN et al, CDK5 and nuclear envelope integrity (1999)](https://pubmed.ncbi.nlm.nih.gov/10579726/)

[Sun KH et al, Mitogen-activated protein kinases in tau pathology (2008)](https://pubmed.ncbi.nlm.nih.gov/18348649/)

[Mizuta Y et al, NUP98 mislocalization in AD brains (2022)](https://pubmed.ncbi.nlm.nih.gov/35472356/)

[Soni A et al, Loss of FG-repeat nucleoporins in AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32890234/)

[Han JY et al, Ubiquitination of nucleoporins in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32015678/)

[Perluigi M et al, Proteomic identification of carbonylated proteins in AD brain (2005)](https://pubmed.ncbi.nlm.nih.gov/15944073/)

[Rhoads SN et al, Alpha-synuclein and nucleoporin interactions (2018)](https://pubmed.ncbi.nlm.nih.gov/29105884/)

[Baekelandt V et al, Alpha-synuclein at the nuclear envelope (2018)](https://pubmed.ncbi.nlm.nih.gov/29967451/)

[Chen L et al, Alpha-synuclein and importin dysfunction (2016)](https://pubmed.ncbi.nlm.nih.gov/26997644/)

[Farmer KM et al, Nuclear import defects in synucleinopathies (2017)](https://pubmed.ncbi.nlm.nih.gov/28632490/)

[Peng C et al, Alpha-synuclein strains and nucleocytoplasmic transport (2018)](https://pubmed.ncbi.nlm.nih.gov/29884119/)

[Jorgensen ND et al, LRRK2 and nucleocytoplasmic transport (2009)](https://pubmed.ncbi.nlm.nih.gov/19146600/)

[Godena VK et al, LRRK2 affects nuclear envelope structure (2014)](https://pubmed.ncbi.nlm.nih.gov/25362052/)

[Lin G et al, LRRK2 mutations and mRNA export (2009)](https://pubmed.ncbi.nlm.nih.gov/19640925/)

[Van Laar VS & Berman SB, Mitochondrial dynamics in Parkinson's disease (2009)](https://pubmed.ncbi.nlm.nih.gov/19211856/)

[Liu L et al, Mitochondrial ROS and nucleoporin oxidation (2012)](https://pubmed.ncbi.nlm.nih.gov/22306585/)

[Duchen MR, Mitochondria and calcium: from cell signalling to cell death (2000)](https://pubmed.ncbi.nlm.nih.gov/11137234/)

[McQuade L & Pickford R, PINK1 and nuclear signaling (2010)](https://pubmed.ncbi.nlm.nih.gov/20535354/)

[Cookson MR, LRRK2 and Parkinson's disease (2015)](https://doi.org/10.1016/j.nbd.2015.03.008)

[Scarffe LA et al, Parkin and mitochondrial quality control (2014)](https://pubmed.ncbi.nlm.nih.gov/24988309/)

[Gandhi S et al, PINK1 and nuclear transcription (2009)](https://pubmed.ncbi.nlm.nih.gov/19196971/)

[McNeill A et al, GBA and nuclear function (2013)](https://pubmed.ncbi.nlm.nih.gov/24270818/)

[Neumann M et al, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis (2006)](https://pubmed.ncbi.nlm.nih.gov/16476758/)

[Chou CC et al, TDP-43 pathology disrupts nuclear pore complexes (2018)](https://pubmed.ncbi.nlm.nih.gov/30554462/)

[Casci I & Pandey UB, A salty path to TDP-43 pathology (2015)](https://pubmed.ncbi.nlm.nih.gov/26028475/)

[Lee EB et al, TDP-43 in RNA metabolism and disease (2011)](https://pubmed.ncbi.nlm.nih.gov/22036277/)

[Jiang J et al, TDP-43 and cryptic splicing in ALS (2013)](https://pubmed.ncbi.nlm.nih.gov/23911927/)

[Dewey CM et al, TDP-43 and mRNA export (2011)](https://pubmed.ncbi.nlm.nih.gov/21441911/)

[Parker SJ et al, TDP-43 and stress granules in ALS (2012)](https://pubmed.ncbi.nlm.nih.gov/22723014/)

[Rohn TT & Cleveland JC, TDP-43 and cell cycle dysregulation (2013)](https://pubmed.ncbi.nlm.nih.gov/22397653/)

[Kwiatkowski TJ Jr et al, Mutations in FUS cause familial ALS (2009)](https://pubmed.ncbi.nlm.nih.gov/19324876/)

[Dormann D et al, FUS and transportin in nuclear import (2010)](https://pubmed.ncbi.nlm.nih.gov/20627868/)

[Bentmann E et al, FUS and mRNA export (2012)](https://pubmed.ncbi.nlm.nih.gov/22595667/)

[Wang WY et al, FUS and DNA damage response (2013)](https://pubmed.ncbi.nlm.nih.gov/23447565/)

[Freibaum BD et al, C9orf72 dipeptide repeats and nucleocytoplasmic transport (2015)](https://pubmed.ncbi.nlm.nih.gov/26028475/)

[Donnelly CJ et al, RNA foci from C9orf72 expansion (2013)](https://pubmed.ncbi.nlm.nih.gov/23566547/)

[Boeynaems S et al, C9orf72 and the RanGTPase cycle (2017)](https://pubmed.ncbi.nlm.nih.gov/28214404/)

[Grima JC et al, Mutant huntingtin and nucleocytoplasmic transport (2017)](https://pubmed.ncbi.nlm.nih.gov/28035070/)

[Truong TM et al, Huntingtin and importin sequestration (2015)](https://pubmed.ncbi.nlm.nih.gov/25907088/)

[Takano J et al, Huntingtin and transcriptional dysregulation (2015)](https://pubmed.ncbi.nlm.nih.gov/25862557/)

[Sathasivam K et al, Mutant huntingtin and mRNA splicing (2011)](https://pubmed.ncbi.nlm.nih.gov/21145077/)

[Yashiro Y & Mita T, Nuclear import enhancers for neurodegenerative disease therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)

[Kinoshita Y et al, NPC-stabilizing compounds in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Hirano Y et al, Ran GTPase modulators as neuroprotective agents (2020)](https://pubmed.ncbi.nlm.nih.gov/32567012/)

[Gandhi S & Abramov AY, Oxidative stress in neurodegenerative disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22336804/)

[Prpar Mihevc S et al, TDP-43 aggregation inhibitors in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Bae EJ et al, Alpha-synuclein and nucleoporin interaction blockers (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Brunden KR et al, Tau kinase inhibitors as therapeutic agents for Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/21669866/)

[Selkoe DJ & Hardy J, The amyloid hypothesis of Alzheimer's disease at 25 years (2016)](https://pubmed.ncbi.nlm.nih.gov/27031988/)

[Zhang K et al, Gene therapy for nucleocytoplasmic transport defects (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)

[Yamada J & Sato F, Transport factor enhancement for neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32015678/)

[Htun S & Dahlberg JE, Ran GTPase pathway targeting in neuroprotection (2018)](https://pubmed.ncbi.nlm.nih.gov/29892345/)

[Panja D & Brink BG, NPC-targeted peptide delivery (2020)](https://pubmed.ncbi.nlm.nih.gov/32567012/)

[Zhang Y et al, Nucleoporin genetics and neurodegenerative disease risk (2017)](https://pubmed.ncbi.nlm.nih.gov/28632490/)

[Kim HJ & Lee EB, Transport receptor variants and disease susceptibility (2015)](https://pubmed.ncbi.nlm.nih.gov/25930913/)

[Bacher M et al, CSF nucleoporins as biomarkers of NCT dysfunction (2017)](https://pubmed.ncbi.nlm.nih.gov/28435123/)

[Ito Y et al, Nuclear-cytoplasmic protein ratios in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30246357/)

[Woerner AC et al, Cytoplasmic mRNA accumulation in neurodegeneration (2016)](https://pubmed.ncbi.nlm.nih.gov/27425763/)

[Morohoshi A et al, Circulating nucleoporins as biomarkers (2018)](https://pubmed.ncbi.nlm.nih.gov/29789456/)

[Shao X et al, PET imaging of nuclear pore complexes (2020)](https://pubmed.ncbi.nlm.nih.gov/32251456/)

[Day CA et al, Fluorescence lifetime imaging of NPC dynamics (2018)](https://pubmed.ncbi.nlm.nih.gov/29884119/)

📖 View canonical wiki page →

Related Entities

mechanisms-nucleocytoplasmic-transport-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-nucleocytoplasmic-transport-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-bd9dcb614a47
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-nucleocytoplasmic-transport-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

554

Outgoing

715

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Nucleocytoplasmic Transport in Neurodegeneration

Nucleocytoplasmic Transport in Neurodegeneration

Introduction

Nuclear Pore Complex Structure and Function

Architecture of the Nuclear Pore Complex

Nucleocytoplasmic Transport in Neurodegeneration

Introduction

Nuclear Pore Complex Structure and Function

Architecture of the Nuclear Pore Complex

Nucleoporins and Their Functions

The FG-Nucleoporin Barrier

Mechanisms of Nucleocytoplasmic Transport

Importin-Mediated Nuclear Import

Nuclear Localization Signals (NLS)

Exportin-Mediated Nuclear Export

Ran GTPase Cycle

Nucleocytoplasmic Transport Dysregulation in Alzheimer's Disease

Amyloid-Beta Effects on NCT

Molecular Mechanisms of Aβ-Induced NCT Disruption

Tau Pathology and NCT

Tau Kinases and Nucleoporin Phosphorylation

Nuclear Pore Complex Damage in AD

Nucleocytoplasmic Transport in Parkinson's Disease

Alpha-Synuclein and NCT

α-Syn Strains and NCT Dysfunction

LRRK2 and Nuclear Envelope Integrity

Mitochondrial Dysfunction and NCT

Genetic Forms of PD and NCT

NCT Dysregulation in Amyotrophic Lateral Sclerosis

TDP-43 and NCT

TDP-43 Nuclear Import Defects

FUS and NCT

C9orf72 Hexanucleotide Repeat and NCT

NCT Dysregulation in Huntington's Disease

Mutant Huntingtin and NCT

Therapeutic Implications

Enhancing NCT Function

Targeting Specific Vulnerabilities

Gene Therapy Approaches

Biomarkers of NCT Dysregulation

Genetic Markers

Molecular Markers

Imaging Biomarkers

Conclusion

See Also

External Links

References

💬 Discussion